Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spruce BiosciencesSPRB -1.25%40 Market Cap is $117.88 Mil as of Aug. 02, 2026. GuruFocus rates SPRB with a GF Score™ of 40/100 and a GF Value™ of $4.08 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,423 Biotechnology companies, Spruce Biosciences ranks better than 50.74% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Spruce Biosciences's share price for the quarter that ended in Mar. 2026 was $65.35. Spruce Biosciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 1.37 Mil. Therefore, Spruce Biosciences's market cap for the quarter that ended in Mar. 2026 was $89.66 Mil.
Spruce Biosciences's quarterly market cap
increased
from Sep. 2025 ($5.04 Mil) to Dec. 2025 ($119.51 Mil) but then
declined
from Dec. 2025 ($119.51 Mil) to Mar. 2026 ($89.66 Mil).
Spruce Biosciences's annual market cap
declined
from Dec. 2023 ($120.20 Mil) to Dec. 2024 ($17.73 Mil) but then
increased
from Dec. 2024 ($17.73 Mil) to Dec. 2025 ($119.51 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Spruce Biosciences's Enterprise Value for Today is $70.92 Mil.
Spruce Biosciences (NAS:SPRB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Spruce Biosciences Market Cap Related Terms
Spruce Biosciences Market Cap Historical Data
* Premium members only.
The historical data trend for Spruce Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Spruce Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spruce Biosciences Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spruce Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Spruce Biosciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Spruce Biosciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spruce Biosciences (SPRB) has a Market Cap of $117.88 Mil as of Aug. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Spruce Biosciences and its competitors. According to the industry distribution chart, Spruce Biosciences ranks #701 out of 1423 companies in the Biotechnology industry, placing it in the top 49.3%.
Is Spruce Biosciences' Market Cap too high?
Spruce Biosciences' current Market Cap is $117.88 Mil. The Biotechnology industry median Market Cap is 112.87. Spruce Biosciences' value of $117.88 Mil is 4.4% above this industry median. Based on the distribution chart, Spruce Biosciences ranks #701 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Spruce Biosciences has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spruce Biosciences' Market Cap compare to VXRT and VTVT?
According to the Biotechnology industry distribution chart, Spruce Biosciences ranks #701 out of 1423 companies for Market Cap. This puts Spruce Biosciences in the upper half of its industry. The industry median Market Cap is 112.87. Spruce Biosciences' value of $117.88 Mil is 4.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.87, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spruce Biosciences's current Market Cap of $117.88 Mil is 4.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Spruce Biosciences and its competitors. For the Biotechnology industry, the median Market Cap is 112.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spruce Biosciences's current Market Cap is $117.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spruce Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Spruce Biosciences (SPRB) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.08, compared to a current price of $42.83 — trading 949.8% above its estimated fair value. The current Market Cap is $117.88 Mil and 4.4% above the Biotechnology industry median of 112.87. Spruce Biosciences' overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Spruce Biosciences (SPRB), the current Market Cap is $117.88 Mil as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spruce Biosciences (SPRB) Overvalued in 2026?
Based on GuruFocus' analysis, Spruce Biosciences stock appears to be overvalued.
The current stock price of $42.83 is trading 949.8% above its estimated GF Value™ of $4.08.
GuruFocus considers Spruce Biosciences to be Significantly Overvalued.
Key valuation signals for SPRB:
Market Cap: $117.88 Mil
GF Value™: $4.08 vs. price of $42.83 (949.8% above fair value)
Industry Position: 4.4% above the Biotechnology median (#701 of 1423)
No single metric tells the full story. See the SPRB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
40GF Score
Get the complete analysis for SPRB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRB has been successfully added to your 
